Advertisement

The Cerebellum

, Volume 18, Issue 2, pp 287–290 | Cite as

Gravity-Independent Upbeat Nystagmus in Syndrome of Anti-GAD Antibodies

  • Daniel Feldman
  • Jorge Otero-Millan
  • Aasef G. ShaikhEmail author
Short Report
  • 137 Downloads

Abstract

An autoimmune disorder of the central nervous system, stiff person syndrome, frequently presents with increased titers of 65KD anti-glutamic acid decarboxylase (anti-GAD) antibodies. The clinical phenomenology of this syndrome includes stiffness, ataxia, vertigo due to horizontal gaze-evoked and downbeat vertical nystagmus, and dysmetria of saccades and reaching movements. Here, we describe a novel phenomenology of syndrome of anti-GAD antibody, non-position-dependent upbeat nystagmus and superimposed horizontal gaze-evoked nystagmus. Lack of gravity dependence of primary position upbeat nystagmus, intense nystagmus on up-gaze, relatively stable gaze on downward orientation, and the exponentially decaying waveform suggests neural integrator dysfunction. The titer of anti-GAD in our patient (30 U/ml) was consistent with a variant called “low-titer anti-GAD syndrome”. In addition of presenting as an unusual manifestation of a rare neurological syndrome, this case presents a neurochemical correlate of upbeat nystagmus in GABA-mediated control system involving horizontal and vertical neural integrators. Furthermore, the variant of “low-titer anti-GAD syndrome” suggests that GABAergic system may be affected at lower level or antibodies, and/or the epitopes of antibody in those with full-blown clinical syndrome, but low titers of anti-GAD may be different.

Keywords

Cerebellum Brainstem Stiff person syndrome Anti-GAD Anti-gliadin 

Introduction

Stiff person syndrome (SPS), an autoimmune disorder of the central nervous system, is known and named after progressive rigidity of the trunk muscles with comorbid spasms [1, 2]. SPS is frequently associated with high titers of anti-glutamic acid decarboxylase (GAD) antibody that is believed to target the brain and spinal cord synapses by affecting the production of the neurotransmitter gamma-aminobutyric acid (GABA) [3]. Such immune attack affects GABA-mediated projections of the cerebellar Purkinje neurons resulting in debilitating forms of ataxia, gait, and eye movement abnormalities. The eye movement impairments in patients with increased titers of anti-GAD antibody include downbeat nystagmus, periodic alternating nystagmus, saccade dysmetria, and reduced accuracy of the smooth pursuit [4, 5, 6, 7, 8, 9, 10, 11]. There have been reports of single cases where increased titers of anti-GAD antibody were associated with isolated unidirectional (ocular flutter) or multidirectional (opsoclonus) [9]. Each type of reported eye movement deficit suggests variable localization in the neuraxis. Downbeat nystagmus, impaired smooth pursuit, and defective vestibulo-ocular reflex (VOR) cancelation localizes to the cerebellar flocculus, while the impaired saccade matrix suggests abnormal function of ocular motor vermis and the fastigial nucleus. Saccadic oscillations and downbeat nystagmus suggested origin at more than one locations. Typically high-frequency saccadic oscillations are localized to disinhibition at saccade burst generators [9, 10, 12, 13, 14], while low frequency of saccadic oscillations can be due to disinhibition of fastigial ocular motor region that remains under cerebellar cortex regulation [10, 15, 16]. Position-dependent vertical nystagmus was recently described in one patient with syndrome of anti-GAD antibody [17]. In supine position, this patient had upbeat nystagmus, while reorientation of the head with respect to gravity in upright resolved upbeat nystagmus; there was emergence of downbeat nystagmus [17]. Alternating skew deviation and hyperactive VOR responses were also present [17]. Such phenomenology of vertical nystagmus was described by disinhibition of the central vestibular pathways carrying posterior semicircular canal signals, due to paucity in GABA-mediated input from the posterior cerebellar vermis, nodulus ventral uvula [17]. Here, we describe a patient with SPS due to abnormally increased but lower than typical titers of anti-GAD antibody (“low-titer anti-GAD antibody syndrome”) who had primary position upbeat nystagmus without gravity-dependent modulation. This report is important from at least two standpoints. From the perspective of neuroimmunology of anti-GAD syndrome, this is a unique manifestation of anti-GAD antibodies that are known to cause the cerebellar syndrome even at lower than usual titers (i.e., putatively novel epitope). From efferent neuro-ophtlhamology standpoint, this case report depicts novel cerebellar controlled neural integrator based theory for upbeat nystagmus, which is traditionally thought to be related to focal lesions in vestibular brainstem.

Patient and Results

A 72-year-old woman with known history of type 1 diabetes had progressive gait instability for 2 years and dysarthria for 8 months. She denied family history of ataxia or gait disturbances. Examination of neurological system revealed primary position upbeat nystagmus that worsened during upgaze. The eye movements were recorded using high-resolution videography and were further investigated off line using frame-by-frame analysis. Figure 1 depicts vertical eye position trace delineating the quantitative kinematic features of the upbeat nystagmus. The waveform had velocity decreasing downward drift (open arrows, Fig. 1), which was followed by an upward quick-phase defining the upbeat nystagmus (closed arrows, Fig. 1). The gaze was stable in downward position. On the lateral gaze, there was symmetric horizontal nystagmus, superimposed upon the upbeat nystagmus. The combination gave an appearance of oblique nystagmus. Pattern or intensity of the nystagmus had no gravity dependence. There was mild hypometria of saccades; pursuit was frequently interrupted by catchup saccades. VOR was normal, but the cancelation of the VOR had saccadic interruptions. There was a marked dysarthria with scanning characteristic of the speech. Dysmetria and kinetic tremor were evident during reaching movements of the finger-to-nose task. The gait was wide-base and markedly ataxic. Neurological examination was otherwise unremarkable.
Fig. 1

Example of upbeat vertical nystagmus during straight-ahead gaze position. Vertical eye positions are plotted on y-axis, while corresponding time is plotted on x-axis. Downward exponentially decaying drifts (open arrows) are followed by rapid upward quick-phases (closed arrows) depicting upbeat nystagmus

MRI brain with and without gadolinium showed mild midline cerebellar atrophy; there was no abnormal enhancement. Hemoglobin A1C revealed uncontrolled diabetes; the levels were at 6.9. The serum titer of anti-GAD 65 antibody was more than 30 U/ml. Three-day course of intravenous methylprednisolone or 5-day course of intravenous immunoglobulin was ineffective in providing symptomatic relief. The patient was followed at 6 months and 1 year, without any subjective or objective change in her symptoms or examination; the nystagmus persisted and had the same phenomenology.

Discussion

The primary position upbeat nystagmus, without gravity dependence, was the unique feature in our patient. The upbeat nystagmus in primary position, in most cases, correlates with intra-axial brainstem lesions. Two main mechanisms and corresponding anatomical localizations have been described. Lesions in the paramedian caudal medulla impair a feedback loop receiving afferents from the vestibular nuclei and projecting to the floccus [18, 19]; involvement of cerebellar feedback loop or otolith projections in caudal medullary lesion can result in gravity-dependent modulation of the upbeat nystagmus [20]. In contrast, the modulation of the upbeat nystagmus according to the eye-in-orbit position, spontaneous upbeat nystagmus in primary position (straight-ahead gaze), its increased intensity in downgaze, and cessation or even direction reversal to the downbeat nystagmus in eccentric gaze suggests dysfunction of neural integrator for vertical gaze holding [21]. The pontine lesions affecting the vestibular efferent tracts to the oculomotor nuclei can manifest in the neural integrator failure [18, 19, 20]. The upbeat nystagmus due to neural integrator dysfunction does not have gravity-dependent modulation; it does not change in lateral gaze, but latter can lead to superimposed horizontal gaze-evoked nystagmus with an oblique eye movement trajectory. The nystagmus due to neural integrator dysfunction also features exponential drift trajectory. Our patient had lack of gravity dependence of primary position upbeat nystagmus; the nystagmus was intense on up-gaze, while the gaze was relatively stable on downward orientation, and the waveform trajectory decayed in exponential manner suggesting neural integrator dysfunction. The lateral gaze holding revealing superimposed horizontal gaze-evoked nystagmus hence causing the oblique trajectory further supports neural integrator dysfunction. Unifying pathophysiological mechanism depicting the dysfunction of horizontal and vertical gaze holding integrator describes the basis for non-gravity-dependent upbeat nystagmus in conjunction with the gaze-evoked horizontal nystagmus in our patient with increased titers of anti-GAD antibody. It is likely that paucity in GABA-mediated projections from the floccular cerebellar Purkinje neurons to the horizontal neural integrators in medulla and vertical neural integrators in mesencephalon results in upbeat and gaze-evoked nystagmus. The paucity in GABA-mediated projections of Purkinje neurons also explains hypometria of saccades and pursuit.

The titers of anti-GAD antibody in our patient (30 U/ml) was lower than typical cases with the same syndrome [22]. Such low-titer anti-GAD antibody syndrome suggests two possibilities. One possibility is that, in presented variant of syndrome of anti-GAD antibody, the antibody epitopes are different compared to usual. Such epitopes can cause GABAergic dysfunction even at the lower titers of antibody. The other possibility is that, early on in the disease course, the patient had high titer of antibodies, and after serial therapies with intravenous immunoglobulin, the titers have reduced but the cerebellum has already acquired irreversible damage manifesting in GABA-mediated syndrome.

Conclusion and Summary

Upbeat nystagmus, an unusual presentation of the syndrome of anti-GAD antibody, sheds further insights into the cerebellar-mediated pathophysiology that involves the neural integrator in generation of upbeat nystagmus.

Notes

Acknowledgements

AS is supported by career development award from the American Academy of Neurology, George C. Cotzias Memorial Fellowship from the American Parkinson’s Disease Association, and Dystonia Medical Research Foundation neural network in dystonia grant.

Funding Information

JO-M is covered by NIH K99 EY027846.

Compliance with Ethical Standards

Conflict of Interest

The authors declare that they have no conflict of interest.

Supplementary material

12311_2018_972_MOESM1_ESM.mp4 (14.3 mb)
ESM 1 (MP4 14,680 kb)

References

  1. 1.
    Solimena M, Folli F, Aparisi R, Pozza G, De Camilli P. Autoantibodies to GABA-ergic neurons and pancreatic beta cells in stiff-man syndrome. N Engl J Med. 1990;322(22):1555–60.CrossRefGoogle Scholar
  2. 2.
    Solimena M, Folli F, Denis-Donini S, Comi GC, Pozza G, De Camilli P, et al. Autoantibodies to glutamic acid decarboxylase in a patient with stiff-man syndrome, epilepsy, and type I diabetes mellitus. N Engl J Med. 1988;318(16):1012–20.CrossRefGoogle Scholar
  3. 3.
    Fouka P, Alexopoulos H, Akrivou S, Trohatou O, Politis PK, Dalakas MC. GAD65 epitope mapping and search for novel autoantibodies in GAD-associated neurological disorders. J Neuroimmunol. 2015;281:73–7.CrossRefGoogle Scholar
  4. 4.
    Ances BM, Dalmau JO, Tsai J, Hasbani MJ, Galetta SL. Downbeating nystagmus and muscle spasms in a patient with glutamic-acid decarboxylase antibodies. Am J Ophthalmol. 2005;140(1):142–4.CrossRefGoogle Scholar
  5. 5.
    Tilikete C, Vighetto A, Trouillas P, Honnorat J. Potential role of anti-GAD antibodies in abnormal eye movements. Ann N Y Acad Sci. 2005;1039:446–54.CrossRefGoogle Scholar
  6. 6.
    Tilikete C, Vighetto A, Trouillas P, Honnorat J. Anti-GAD antibodies and periodic alternating nystagmus. Arch Neurol. 2005;62(8):1300–3.CrossRefGoogle Scholar
  7. 7.
    Economides JR, Horton JC. Eye movement abnormalities in stiff person syndrome. Neurology. 2005;65(9):1462–4.CrossRefGoogle Scholar
  8. 8.
    Markakis I, Alexiou E, Xifaras M, Gekas G, Rombos A. Opsoclonus-myoclonus-ataxia syndrome with autoantibodies to glutamic acid decarboxylase. Clin Neurol Neurosurg. 2008;110(6):619–21.CrossRefGoogle Scholar
  9. 9.
    Shaikh AG, Wilmot G. Opsoclonus in a patient with increased titers of anti-GAD antibody provides proof for the conductance-based model of saccadic oscillations. J Neurol Sci. 2016;362:169–73.CrossRefGoogle Scholar
  10. 10.
    Shaikh AG, Marti S, Tarnutzer AA, Palla A, Crawford TO, Straumann D, et al. Gaze fixation deficits and their implication in ataxia-telangiectasia. J Neurol Neurosurg Psychiatry. 2009;80(8):858–64.CrossRefGoogle Scholar
  11. 11.
    Zivotofsky AZ, Siman-Tov T, Gadoth N, Gordon CR. A rare saccade velocity profile in stiff-person syndrome with cerebellar degeneration. Brain Res. 2006;1093(1):135–40.CrossRefGoogle Scholar
  12. 12.
    Ramat S, Leigh RJ, Zee DS, Shaikh AG, Optican LM. Applying saccade models to account for oscillations. Prog Brain Res. 2008;171:123–30.CrossRefGoogle Scholar
  13. 13.
    Shaikh AG, Miura K, Optican LM, Ramat S, Leigh RJ, Zee DS. A new familial disease of saccadic oscillations and limb tremor provides clues to mechanisms of common tremor disorders. Brain. 2007;130(Pt 11):3020–31.CrossRefGoogle Scholar
  14. 14.
    Shaikh AG, Ramat S, Optican LM, Miura K, Leigh RJ, Zee DS. Saccadic burst cell membrane dysfunction is responsible for saccadic oscillations. J Neuroophthalmol. 2008;28(4):329–36.CrossRefGoogle Scholar
  15. 15.
    Jen JC, Lopez I, Baloh RW. Opsoclonus: clinical and immunological features. J Neurol Sci. 2012;320(1–2):61–5.CrossRefGoogle Scholar
  16. 16.
    Wong AM, Musallam S, Tomlinson RD, Shannon P, Sharpe JA. Opsoclonus in three dimensions: oculographic, neuropathologic and modelling correlates. J Neurol Sci. 2001;189(1–2):71–81.CrossRefGoogle Scholar
  17. 17.
    Martins AI, Carvalho JN, Amorim AM, Geraldo A, Eggenberger E, Lemos J. Disabling central paroxysmal positioning upbeat nystagmus and vertigo associated with the presence of anti-glutamic acid decarboxylase antibodies. J Neuroophthalmol. 2018;38(1):32–5.CrossRefGoogle Scholar
  18. 18.
    Pierrot-Deseilligny C, Milea D. Vertical nystagmus: clinical facts and hypotheses. Brain. 2005;128(Pt 6):1237–46.CrossRefGoogle Scholar
  19. 19.
    Pierrot-Deseilligny C, Milea D, Sirmai J, Papeix C, Rivaud-Pechoux S. Upbeat nystagmus due to a small pontine lesion: evidence for the existence of a crossing ventral tegmental tract. Eur Neurol. 2005;54(4):186–90.CrossRefGoogle Scholar
  20. 20.
    Fisher A, Gresty M, Chambers B, Rudge P. Primary position upbeating nystagmus. A variety of central positional nystagmus. Brain. 1983;106(Pt 4):949–64.CrossRefGoogle Scholar
  21. 21.
    Shin BS, Oh SY, Kim JS, Lee H, Kim EJ, Hwang SB. Upbeat nystagmus changes to downbeat nystagmus with upward gaze in a patient with Wernicke’s encephalopathy. J Neurol Sci. 2010;298(1–2):145–7.CrossRefGoogle Scholar
  22. 22.
    Nanri K, Niwa H, Mitoma H, Takei A, Ikeda J, Harada T, et al. Low-titer anti-GAD-antibody-positive cerebellar ataxia. Cerebellum. 2013;12(2):171–5.CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  • Daniel Feldman
    • 1
  • Jorge Otero-Millan
    • 2
  • Aasef G. Shaikh
    • 1
    Email author
  1. 1.Department of Neurology, Cleveland VA Medical CenterUniversity HospitalsClevelandUSA
  2. 2.Department of NeurologyJohns Hopkins UniversityBaltimoreUSA

Personalised recommendations